Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
32
KALA Quote, Financials, Valuation and Earnings
Last price:
$0.62
Seasonality move
:
14.64%
Day range:
$0.53 - $0.56
52-week range:
$0.51 - $20.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.18x
P/B ratio:
8.34x
Volume:
815K
Avg. volume:
15M
1-year change:
-91.94%
Market cap:
$5.1M
Revenue:
--
EPS (TTM):
-$5.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
-- | -$1.10 | -- | -43.13% | $1.50 |
|
ALLO
Allogene Therapeutics, Inc.
|
$1.8K | -$0.22 | -92.41% | -21.56% | $7.56 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.51 | -- | -58.83% | $184.33 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
QTTB
Q32 Bio, Inc.
|
-- | -- | -100% | -- | $15.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
$0.62 | $1.50 | $5.1M | -- | $0.00 | 0% | 7.18x |
|
ALLO
Allogene Therapeutics, Inc.
|
$1.35 | $7.56 | $303.4M | -- | $0.00 | 0% | 2,442.58x |
|
BLTE
Belite Bio, Inc.
|
$159.27 | $184.33 | $6B | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$5.15 | $42.50 | $15.6M | -- | $0.00 | 0% | -- |
|
PMCB
PharmaCyte Biotech, Inc.
|
$0.74 | -- | $7.5M | 0.40x | $0.00 | 0% | 239.61x |
|
QTTB
Q32 Bio, Inc.
|
$3.44 | $15.00 | $42.3M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
140.72% | 2.141 | 263.3% | 0.65x |
|
ALLO
Allogene Therapeutics, Inc.
|
21.26% | -0.424 | 30.77% | 7.92x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.792 | 0.02% | 34.17x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | 1.303 | 0.49% | 9.89x |
|
QTTB
Q32 Bio, Inc.
|
-1196.42% | 2.670 | 69.88% | 4.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KALA
Kala Bio, Inc.
|
-$128K | -$10.7M | -102.67% | -1375.54% | -- | -$10.9M |
|
ALLO
Allogene Therapeutics, Inc.
|
-$3.1M | -$44.9M | -44.62% | -54.89% | -315927.27% | -$29.9M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | -$1.4M | -16.43% | -16.43% | -- | -$979.5K |
|
QTTB
Q32 Bio, Inc.
|
-$91K | -$7.6M | -256.32% | -634.27% | -- | -$4.2M |
Kala Bio, Inc. vs. Competitors
-
Which has Higher Returns KALA or ALLO?
Allogene Therapeutics, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of -295454.55%. Kala Bio, Inc.'s return on equity of -1375.54% beat Allogene Therapeutics, Inc.'s return on equity of -54.89%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M -
What do Analysts Say About KALA or ALLO?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 141.51%. On the other hand Allogene Therapeutics, Inc. has an analysts' consensus of $7.56 which suggests that it could grow by 460%. Given that Allogene Therapeutics, Inc. has higher upside potential than Kala Bio, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 ALLOAllogene Therapeutics, Inc.9 2 0 -
Is KALA or ALLO More Risky?
Kala Bio, Inc. has a beta of -2.429, which suggesting that the stock is 342.929% less volatile than S&P 500. In comparison Allogene Therapeutics, Inc. has a beta of 0.512, suggesting its less volatile than the S&P 500 by 48.816%.
-
Which is a Better Dividend Stock KALA or ALLO?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Allogene Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or ALLO?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Allogene Therapeutics, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than Allogene Therapeutics, Inc.'s net income of -$41.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Allogene Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 2,442.58x for Allogene Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M
-
Which has Higher Returns KALA or BLTE?
Belite Bio, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About KALA or BLTE?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 141.51%. On the other hand Belite Bio, Inc. has an analysts' consensus of $184.33 which suggests that it could grow by 15.74%. Given that Kala Bio, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Kala Bio, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 BLTEBelite Bio, Inc.5 0 0 -
Is KALA or BLTE More Risky?
Kala Bio, Inc. has a beta of -2.429, which suggesting that the stock is 342.929% less volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KALA or BLTE?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or BLTE?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Belite Bio, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than Belite Bio, Inc.'s net income of -$21.7M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns KALA or CVM?
CEL-SCI Corp. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About KALA or CVM?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 141.51%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 725.24%. Given that CEL-SCI Corp. has higher upside potential than Kala Bio, Inc., analysts believe CEL-SCI Corp. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 CVMCEL-SCI Corp.1 0 0 -
Is KALA or CVM More Risky?
Kala Bio, Inc. has a beta of -2.429, which suggesting that the stock is 342.929% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock KALA or CVM?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or CVM?
Kala Bio, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns KALA or PMCB?
PharmaCyte Biotech, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat PharmaCyte Biotech, Inc.'s return on equity of -16.43%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M PMCBPharmaCyte Biotech, Inc.-- -$1.24 $36.1M -
What do Analysts Say About KALA or PMCB?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 141.51%. On the other hand PharmaCyte Biotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kala Bio, Inc. has higher upside potential than PharmaCyte Biotech, Inc., analysts believe Kala Bio, Inc. is more attractive than PharmaCyte Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 PMCBPharmaCyte Biotech, Inc.0 0 0 -
Is KALA or PMCB More Risky?
Kala Bio, Inc. has a beta of -2.429, which suggesting that the stock is 342.929% less volatile than S&P 500. In comparison PharmaCyte Biotech, Inc. has a beta of 0.038, suggesting its less volatile than the S&P 500 by 96.158%.
-
Which is a Better Dividend Stock KALA or PMCB?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PharmaCyte Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. PharmaCyte Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or PMCB?
Kala Bio, Inc. quarterly revenues are --, which are smaller than PharmaCyte Biotech, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is lower than PharmaCyte Biotech, Inc.'s net income of -$7.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while PharmaCyte Biotech, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 239.61x for PharmaCyte Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M PMCBPharmaCyte Biotech, Inc.239.61x 0.40x -- -$7.4M
-
Which has Higher Returns KALA or QTTB?
Q32 Bio, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat Q32 Bio, Inc.'s return on equity of -634.27%.
Company Gross Margin Earnings Per Share Invested Capital KALAKala Bio, Inc.-- -$1.07 $21.3M QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M -
What do Analysts Say About KALA or QTTB?
Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 141.51%. On the other hand Q32 Bio, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 336.05%. Given that Q32 Bio, Inc. has higher upside potential than Kala Bio, Inc., analysts believe Q32 Bio, Inc. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALAKala Bio, Inc.0 2 0 QTTBQ32 Bio, Inc.1 1 0 -
Is KALA or QTTB More Risky?
Kala Bio, Inc. has a beta of -2.429, which suggesting that the stock is 342.929% less volatile than S&P 500. In comparison Q32 Bio, Inc. has a beta of 0.134, suggesting its less volatile than the S&P 500 by 86.587%.
-
Which is a Better Dividend Stock KALA or QTTB?
Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Q32 Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Q32 Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALA or QTTB?
Kala Bio, Inc. quarterly revenues are --, which are smaller than Q32 Bio, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is lower than Q32 Bio, Inc.'s net income of -$7.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Q32 Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for Q32 Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALAKala Bio, Inc.7.18x -- -- -$7.6M QTTBQ32 Bio, Inc.-- -- -- -$7.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 5
Claritev Corp. [CTEV] is down 18.95% over the past day.
Buy
60
BIDU alert for Jan 5
Baidu, Inc. [BIDU] is down 3.94% over the past day.
Sell
47
ASTS alert for Jan 5
AST Spacemobile, Inc. [ASTS] is up 14.55% over the past day.
